MedTrace Logo

Zevalin Post-marketing Surveillance in Japan

NCT01448928 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2021-10-01

No results posted yet for this study

Summary

This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Zevalin for relapsed or refractory, CD20+, low grade B-cell non-Hodgkin's lymphoma and Mantle cell lymphoma. The objective of this study is to assess safety and efficacy of using Zevalin in clinical practice. This study is also all case investigation of which the enrollment period is five years, and all patients who received Zevalin will be recruited and followed 13 weeks after the administration.

Conditions

  • Non-Hodgkin's Lymphoma (NHL)

Interventions

DRUG

[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)

Patients who have received Zevalin for relapsed or refractory, CD20+, low grade B-cell non-Hodgkin's lymphoma and Mantle cell lymphoma.

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Spectrum Pharmaceuticals, Inc

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2018-01-31
Completion
2018-01-31

Countries

  • Japan

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01448928 on ClinicalTrials.gov